Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Radiochemotherapy is a standard for the treatment of unresectable stage III non-small cell
lung cancer. The investigators goal is to study the efficacy and the toxicity for a promising
association of new agents (cetuximab and pemetrexed) with concurrent radiotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique